Dyne therapeutics logo
WebDyne Therapeutics is registered under the ticker NASDAQ:DYN . Their stock opened with $19.00 in its Sep 16, 2024 IPO. Dyne Therapeutics is funded by 9 investors. Logos … WebOct 1, 2024 · Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to …
Dyne therapeutics logo
Did you know?
WebMar 20, 2024 · positioned for growth. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people … Mar 10, 2024: 8-K: Report of unscheduled material events or corporate event. … The Investor Relations website contains information about Dyne Therapeutics, … Amy Reilly. Senior Vice President, Corporate Communications & Investor … Dyne logo. Our Focus Our FORCE TM Platform Pipeline About Us Investors & … WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically …
WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary ... WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1).
WebApr 11, 2024 · Dyne Therapeutics Stock Performance. NASDAQ DYN opened at $8.82 on Tuesday. The stock has a market cap of $496.90 million, a price-to-earnings ratio of -2.72 and a beta of 0.24. WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically …
WebFeb 8, 2024 · Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its ...
shark sofa cleanerWebFeb 9, 2024 · 1 to 50 Employees. Founded: 2024. Type: Company - Public (DYN) Industry: Biotech & Pharmaceuticals. Revenue: Less than $1 million (USD) Competitors: Unknown. sharks off california coastWebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … sharks ocean city marylandWebApr 10, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they expect the company's stock price to reach $25.83 in the next year. This suggests a possible upside of 175.4% from the stock's current price. populate field in accessWebJan 14, 2024 · --Dyne Therapeutics, Inc., a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S ... sharks off long islandWebMar 14, 2024 · 天眼查为您提供Dyne Therapeutics Inc.的企业信息查询服务，查询Dyne Therapeutics Inc.工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、公司发展状况、公司财务状况、公司股东法人高管、商标、融资、专利、法律诉讼等Dyne Therapeutics Inc.企业信用信息，想了解Dyne Therapeutics Inc.怎么样，就 ... populate inorder successor for all nodes gfgWebWho invested in Dyne Therapeutics? Dyne Therapeutics has 9 investors including Logos Capital and Wellington Management. How much funding has Dyne Therapeutics raised to date? Dyne Therapeutics has raised $333M. When was the last funding round for Dyne Therapeutics? Dyne Therapeutics closed its last funding round on Jan 21, 2024 from a … sharks offer 55% stake